Back to Search
Start Over
The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.
- Source :
-
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2023 Jun 09; Vol. 31 (7), pp. 386. Date of Electronic Publication: 2023 Jun 09. - Publication Year :
- 2023
-
Abstract
- Purpose: The purpose of this retrospective cohort study was to evaluate whether several potentially preventive therapies reduced the rate of oxaliplatin-induced peripheral neuropathy (OIPN) in colorectal cancer patients and to assess the relationship of sociodemographic/clinical factors with OIPN diagnosis.<br />Methods: Data were obtained from the Surveillance, Epidemiology, and End Results database combined with Medicare claims. Eligible patients were diagnosed with colorectal cancer between 2007 and 2015, ≥ 66 years of age, and treated with oxaliplatin. Two definitions were used to denote diagnosis of OIPN based on diagnosis codes: OIPN 1 (specific definition, drug-induced polyneuropathy) and OIPN 2 (broader definition, additional codes for peripheral neuropathy). Cox regression was used to obtain hazard ratios (HR) with 95% confidence intervals (CI) for the relative rate of OIPN within 2 years of oxaliplatin initiation.<br />Results: There were 4792 subjects available for analysis. At 2 years, the unadjusted cumulative incidence of OIPN 1 was 13.1% and 27.1% for OIPN 2. For both outcomes, no therapies reduced the rate of OIPN diagnosis. The anticonvulsants gabapentin and oxcarbazepine/carbamazepine were associated with an increased rate of OIPN (both definitions) as were increasing cycles of oxaliplatin. Compared to younger patients, those 75-84 years of age experienced a 15% decreased rate of OIPN. For OIPN 2, prior peripheral neuropathy and moderate/severe liver disease were also associated with an increased hazard rate. For OIPN 1, state buy-in health insurance coverage was associated with a decreased hazard rate.<br />Conclusion: Additional studies are needed to identify preventive therapeutics for OIPN in cancer patients treated with oxaliplatin.<br /> (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Subjects :
- United States
Humans
Aged
Oxaliplatin adverse effects
Retrospective Studies
Organoplatinum Compounds adverse effects
Medicare
Antineoplastic Agents adverse effects
Peripheral Nervous System Diseases chemically induced
Peripheral Nervous System Diseases epidemiology
Peripheral Nervous System Diseases prevention & control
Colorectal Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1433-7339
- Volume :
- 31
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 37294347
- Full Text :
- https://doi.org/10.1007/s00520-023-07850-z